This therapeutic strategy targets USP13 (Ubiquitin-Specific Peptidase 13), a deubiquitinating enzyme that counteracts the ubiquitin-tagging of both Parkin and α-synuclein, thereby blocking their proteasomal degradation and impairing PINK1-Parkin mitophagy. Pharmacological inhibition of USP13 would restore ubiquitin-dependent clearance of damaged mitochondria and toxic α-synuclein species even in neurons with impaired Parkin function — a common feature of both familial and sporadic Parkinson's disease.[1][2]
The PINK1-Parkin mitophagy pathway is the principal quality-control mechanism for damaged mitochondria in neurons.[5] When mitochondrial membrane potential collapses, PINK1 accumulates on the outer membrane and recruits Parkin, which ubiquitinates mitochondrial surface proteins to flag them for autophagic clearance.[6] USP13 directly opposes this process at two levels:
Genetic knockdown of USP13 in MPTP-treated mice dramatically rescued dopaminergic neuron survival, reduced α-synuclein accumulation, and restored mitochondrial function — even with partial Parkin deficiency.[1:2]
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9/10 | USP13 is a virtually unexplored clinical target; no DUB inhibitors in neurodegeneration trials |
| Mechanistic Rationale | 8/10 | Strong genetic and pharmacological evidence in PD mouse models; clear molecular mechanism |
| Addresses Root Cause | 8/10 | Directly restores mitochondrial quality control and α-synuclein clearance — two core PD pathologies |
| Delivery Feasibility | 7/10 | Small-molecule DUB inhibitors are well-precedented in oncology; BBB penetration achievable |
| Safety Plausibility | 6/10 | USP13 has broad substrate repertoire; selectivity engineering needed to avoid off-target deubiquitination |
| Combinability | 8/10 | Orthogonal to dopaminergic therapies, anti-inflammatory approaches, and GCase activators like ambroxol |
| Biomarker Availability | 7/10 | CSF α-synuclein seed amplification, NfL, and mitochondrial-derived vesicle markers can track target engagement |
| De-risking Path | 7/10 | iPSC-derived dopaminergic neuron models with PINK1/PRKN mutations available; MPTP mouse model validated |
| Multi-disease Potential | 7/10 | Applicable to PD, DLB, MSA (synucleinopathies), and potentially AD (mitophagy impairment) and ALS (TDP-43 ubiquitin pathology) |
| Patient Impact | 8/10 | Could halt dopaminergic neuron loss if administered early; disease-modifying rather than symptomatic |
| Total | 75/100 |
iPSC Neuron Validation
Hit Discovery Campaign
Selectivity Profiling
First-in-Human Study Design
Patient Population
| Partner Type | Target Organization | Rationale |
|---|---|---|
| Pharma | AbbVie, BMS, Pfizer | Existing DUB inhibitor programs; oncology-to-neuro pipeline interest |
| Biotech | NeuBase, Prothelia | Gene therapy and antisense capabilities |
| Academic | Michael J. Fox Foundation | Preclinical consortia, patient cohorts |
| Academic | CEP (Center for Neurodegeneration Research) | iPSC lines, PD models |
| VC | Andreessen Horowitz, ARCH, GV | Neurodegeneration-focused funds |
| Grant | Agency | Amount | Focus | Deadline |
|---|---|---|---|---|
| R21 | NIH/NINDS | $275K | Target validation, hit-to-lead | April 2026 |
| U01 | NIH/NINDS | $3M | Preclinical development | Sept 2026 |
| SBIR Phase I | NIH | $300K | Drug discovery | Rolling |
| MJFF Therapeutics | Michael J. Fox | $500K-1M | PD drug development | Q2 2026 |
| ASAP | Aligning Science Across Parkinson's | $500K-2M | Preclinical consortia | Q1, Q3 |
| Phase | Estimated Cost | Duration |
|---|---|---|
| Target Validation | $150K | 6 months |
| Hit Discovery & SAR | $500K | 12 months |
| Lead Optimization | $1.5M | 18 months |
| IND-enabling studies | $3M | 12 months |
| Phase 1 | $5M | 24 months |
| Total to Phase 1 | ~$10M | ~72 months |
| Disease | Relevance | Rationale |
|---|---|---|
| Parkinson's Disease | High | Core PINK1-Parkin pathway defect; α-synuclein accumulation |
| Dementia with Lewy Bodies | High | Shared synuclein pathology with cortical involvement |
| Multiple System Atrophy | Medium | Oligodendroglial α-synuclein aggregation; mitophagy role less clear |
| Alzheimer's Disease | Medium | Mitophagy impairment documented; Parkin deficiency in hippocampal neurons[8] |
| ALS/FTD | Low | TDP-43 ubiquitin pathology present but USP13 role not validated[9] |
Target Validation
Lead Identification
Medicinal Chemistry
Preclinical Development
IND-enabling studies
Clinical Trials
Estimated Cost to IND: $8-12M
Estimated Cost Phase 1-2: $25-40M
Liu X, Hebron M, Bhatt P, et al. Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies. Human Molecular Genetics. 2019. ↩︎ ↩︎ ↩︎
Liu X, Hebron ML, Mulki S, et al. USP13 antagonizes gp78 to maintain functionality of the ubiquitin proteasome system. eLife. 2019. ↩︎ ↩︎
Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annual Review of Biochemistry. 2017. ↩︎
Bingol B, Tea JS, Phu L, et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature. 2014. ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015. ↩︎
Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Journal of Cell Biology. 2008. ↩︎
Harper JW, Ordureau A, Heo JM. Building and decoding ubiquitin chains for mitophagy. Nature Reviews Molecular Cell Biology. 2018. ↩︎
Hebron ML, Lonskaya I, Ober V, et al. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in alpha-synucleinopathy. Journal of Clinical & Cellular Immunology. 2014. ↩︎
Peng J, Schwartz D, Elias JE, et al. A proteomics approach to understanding protein ubiquitination. Nature Biotechnology. 2003. ↩︎
Durcan TM, Fon EA. The three P's of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes & Development. 2015. ↩︎